Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering is a promising company due to its innovative Disease Cancelling Technology platform, which has shown potential in treating RAS-driven tumors and preventing resistant disease. The upcoming MAPKeeper 301 trial will provide further validation for their drug atebimetinib, and the company's interactions with the FDA support their approach. While there are risks involved, long-term investors could see significant upside.

Bears say

Immuneering is facing several challenges with its drug development program, including potential competitiveness and low success rates in phase 3 trials. The company also relies heavily on patents and trade secrets for protection, which may pose risks if competitors develop similar treatments. This could lead to downward revisions in projections and price targets, while also requiring additional financing to support its drug development efforts.

Immuneering Corp (IMRX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immuneering Corp (IMRX) has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.